ATAI Life Sciences BV Total Liabilities

Latest as of March 2026: $66.10 Million USD

ATAI Life Sciences BV total liabilities. Based on the latest financial reports, ATAI Life Sciences BV (ATAI) has total liabilities worth $66.10 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ATAI Life Sciences BV (ATAI) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of ATAI Life Sciences BV (2019–2025)

Total liabilities of ATAI Life Sciences BV from 2019 to 2025. This chart illustrates how ATAI Life Sciences BV's total liabilities have evolved over time, based on quarterly financial data. Explore ATAI Life Sciences BV long-term investment intensity to see how much of total assets are deployed in long-term investments.

ATAI Life Sciences BV Competitors by Total Liabilities

The table below lists competitors of ATAI Life Sciences BV ranked by their total liabilities.

Company Country Total Liabilities
Gold Road Resources Ltd
AU:GOR
Australia AU$382.05 Million
Disc Medicine Inc.
NASDAQ:IRON
USA $90.91 Million
FRASERS PROPERTY
F:1IQ
Germany €22.95 Billion
President Securities Corp
TW:2855
Taiwan NT$178.21 Billion
Shikun & Binui
TA:SKBN
Israel ILA19.53 Billion
AVIC Heavy Machinery Co Ltd
SHG:600765
China CN¥14.55 Billion
PT Petrindo Jaya Kreasi Tbk
JK:CUAN
Indonesia Rp1.57 Billion
Foxconn Technology Co Ltd
TW:2354
Taiwan NT$64.84 Billion

Liability Composition Analysis (2019–2025)

This chart breaks down ATAI Life Sciences BV's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ATAI Life Sciences BV (ATAI) total assets.

Liquidity & Leverage Metrics

ATAI Life Sciences BV Total Liabilities Ratios Explained

ATAI Life Sciences BV total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 10.02 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.33 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.25 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how ATAI Life Sciences BV's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for ATAI Life Sciences BV (2019–2025)

The table below shows the annual total liabilities of ATAI Life Sciences BV from 2019 to 2025.

Year Total Liabilities Change
2025-12-31 $88.54 Million +106.71%
2024-12-31 $42.83 Million -12.87%
2023-12-31 $49.16 Million +23.91%
2022-12-31 $39.67 Million +40.66%
2021-12-31 $28.21 Million +74.33%
2020-12-31 $16.18 Million +592.64%
2019-12-31 $2.34 Million --

About ATAI Life Sciences BV

NASDAQ:ATAI USA Biotechnology
Market Cap
$2.73 Billion
Market Cap Rank
#5063 Global
#1730 in USA
Share Price
$7.35
Change (1 day)
+0.00%
52-Week Range
$3.35 - $7.44
All Time High
$19.89
About

AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder… Read more